

# High Probability MS Identification of Phosphopeptides by their Mass Defect Erol E. Gulcicek<sup>2</sup>, Mark Shifman<sup>1</sup>, Perry Miller<sup>1</sup>, Christopher M. Colangelo<sup>2</sup>, Kathryn L. Stone<sup>2</sup>, Matthew Berberich<sup>2</sup>, TuKiet T. Lam<sup>2</sup>, Can Bruce<sup>1</sup> **Yale University**

# **Overview / Introduction**

The mass defect (the difference between the actual and nominal monoisotopic mass) of the phosphate group is smaller than that of most atoms present in proteins. When the mass defects of tryptic peptides derived from the human proteome are plotted against their masses, phosphopeptides tend to fall off the regression line. In this study, we explored whether this characteristic of phosphorylated peptides can be used to distinguish them with high probability from unphosphorylated peptides.

# Background

Various techniques have been developed in recent years that uses the mas defect principle to facilitate the identification and quantitation of peptides (see 1) for a review). We demonstrate the concept of fractional mass to be able to detect phosphopeptides apart from their more abundant unphosphorylated ounterparts in a mass spectrometer. When using a tandem MS-MS instrument or biological mass spectrometry, it is difficult to determine if a particular peptide s phosphorylated in the "survey mode" of operation. As a result, valuable time is spent using the mass spectrometer for sequence determination of unphosphorylated peptides that are generally the most abundant peptides. This time commitment may be in excess of the time window in which a transient species nay be available for analysis, particularly if the MS-MS is coupled to an online chemical separation technique such as liquid chromatography or capillary elec rophoresis.

The concept uses theoretical negative mass shift behavior of phosphopeptides and assigns probabilities to these peptides (Bruce et al. 2006) that can be dis tinctively selected for MS/MS processing before the more abundant unphosphorylated peptides. This idea can be implemented in real time to first rank order probabilities of peptides for being a phosphopeptide and preferentially decide the order of acquisition for MS/MS from a list of possible peptides. The assigned probability would also increase the confidence and the probability of identification of many phosphopeptides.


	Mass	Mass Defect
<sup>12</sup> C	12.0000000	+0.0000000
<sup>14</sup> N	14.0030740	+0.0030740
<sup>1</sup> H	1.0078250	+0.0078250
<sup>16</sup> O	15.9949146	-0.0050854
<sup>32</sup> S	31.9720707	-0.0279293
<sup>31</sup> P	30.9737615	-0.0262385
PO <sub>3</sub>	79.9663304	-0.0336696
ler	87.0320284	+0.0320284
SerSer	175.0713333	+0.0713333
oSer	168.0056353	+0.0056353

**Fractional Mass:** Mass value to the right of the

lecimal point. Up to 0.999..., Fractional Mass and Mass Defect


are equal. Above ~1500 Daltons, mass defect is 1.0, while fractional mass cycles back to stay in the range of [0 - 0.99...].

# **Methods**



# Center for Medical Informatics<sup>1</sup>, W.M. Keck Foundation Biotechnology Resource Laboratory<sup>2</sup>

### Results



http://phosphopeptide.med.yale.edu/


search form to find phosphopeptide probabilities

We developed a transformation function to calculate the mass defect of a peptide from its mass:

Calculated Mass Defect = int( aM+b - int(aM+b) - F ) + int(aM+b) + aM+b + F

where the function int(x) returns the greatest integer smaller than x, M is monoisotopic mass, F for fractional mass (that is, M-int(M)) and a and b are constants.

Using this formula, 98.8% of all peptides have the correct calculated Mass Defect value, The mismatches occurring at the edges of the data cloud where the addition of the correct integer value to the fractional mass is more prone to error (see Fig 5 and 6). These errors primarily occur above 4000 Da, while most real mass spectrometric peaks are observed below this mass.



#### Phosphorylation probability distribution maps.

Figure 3. Phosphorylation probability distribution map as a function of Monoisotopic Mass and Fractional Mass. Color Map shows probability of phosphorylation for each pixel of 10 Da Mass x 0.01 Da Fractional Mass.

Figure 4. Phosphorylation probability distribution map as a function of Monoisotopic Mass and calculated Mass Defect.

Figure 5. Phosphorylation probability distribution map as a function of Monoisotopic Mass and true Mass Defect.

#### Phosphorylation probability contour maps

Figure 7. Probability distribution data in Fig. 5, above, re-plotted as a contour map to show linearity of selected contour lines. Note different scale of the graph axes.

Each of these contour lines can be fitted by regression lines (y=ax+b). For example, the parameters for the p=0.9 line are  $a = 0.000457 \pm 0.0000006$  $b = -0.0448 \pm 0.0029$ 

Peptides that fall below the blue line in the figure have a probability >0.9 of having 1, 2, or 3 phosphate groups.

PROPOSED PHOSPHOPEPTIDE SELECTION PROCESS Get experimental monoisotopic parent mass User selects probability threshold, eg. 90%

Compare experimental to calculated boundary mass defect values


Accept/Reject phosphopeptide presence for MS/MS


### References

- (1) Kersey, et al. (2004) *Proteomics* 4, 1985-1988.
- (2) Diella, et al. (2004) *BMC Bioinformatics* 5, 79.
- (3) Schneider and Hall (2005) Drug Discovery Today, 10:353-363.
- (4) Bruce, et al. (2006) Anal Chem. (Accepted; Published on Web 05/13/06)



Figure 8. Preliminary testing of the algorithm with SCX enriched phosphopeptides






Digested Protein Sample from mouse kidney cell lines (225µg) is enriched for phosphopeptides using SCX chromatography. 600 peptides were identified from the 24 early fractions with a MASCOT score of 35 and higher. The early SCX fractions were combined to run in 4 RP LC MS/MS runs with our QSTAR mass spectrometer. Of the 600 identified peptides 24 were phosphorylated. The above two figures show the fractional mass (left) and the phosphopeptide probability distributions (right) for the 600 identified peptides. The complete experiment with 14 LC-MS/MS runs resulted in 888 protein ID's with ProteinProphet Probability of 0.9 and higher. Of these, 37 were phosphoproteins.

#### The p=0.9 line is highly reliable in identifying phosphopeptides up to a mass measurement accuracy of 20 ppm.

Table 2. Positive Predictive Value, TP/(TP+FP), of p=0.9 Line as a Function of Simulated Mass Measurement Error

				1,2 or 3
Error	1 Phos	2 Phos	3 phos	Phos
0 ppm	80.6%	89.1%	89.5%	95.4%
1 ppm	80.6%	89.1%	89.5%	95.4%
5 ppm	80.4%	88.8%	89.2%	95.3%
20 ppm	76.9%	85.1%	85.0%	93.6%
100 ppm	55.2%	53.5%	46.0%	76.4%



Each peptide's mass was modified by an error term 50 times and each time its calculated mass defect was compared with the L<sub>0.9</sub> line. Numbers (except for the 0 ppm error) are the averages of these 50 independent determinations. Standard deviations are less than 0.1% of the means.

TP (true positive), phosphopeptide and below the line; FP (false positive), unphosphorylated peptide and below the line

### **Conclusions and Future Work**

- The mass defect of tryptic peptides can be calculated with high accuracy based on their mass.
- Peptides can be classified with a simple formula for their phosphorylation probability, based on their mass and their calculated mass defect.
- ~41% of potential phosphopeptides (with 1,2 or 3 phosphates) can be identified with a probability >0.90 for peptides of Mass < 4000 Da.
- The categorization of a peptide as being phosphorylated has a positive predictive value >0.96 for Mass < 4000 Da.
- The categorization of a peptide as being phosphorylated is relatively insensitive to mass measurement accuracy up to 20 ppm.
- Experimentally validated phosphopeptides are similarly partitioned by the p=0.9 line as all potential phosphopeptides derived from the human proteome.
- An algorithm based on this formula can be used to automatically route such peptides to MS/MS analysis. (Yale University Office of Cooperative Research Invention tracking # 4048)

## Acknowledgements

This project has been funded in part with federal funds from NHLBI contract (N01-HV-28186) and NIDA Neuroproteomics grant 1 P30 DA018343. CB is funded by NIH grant T15 LM07056 from the National Library of Medicine.